Generex Biotechnology (GNBT) – StreetInsider.com Reports
-
Generex Biotechnology (GNBT) Announces Plans for Breast Cancer Vaccine Spinout and Dividend
-
Generex Biotechnology (GNBT) Announces Update on NuGenerex Immuno-Oncology
-
Generex Biotechnology (GNBT) Subsidiary Regentys Corp. Granted European Patent Approval for ECMH for Treatment of Ulcerative Colitis
-
Generex Biotechnology (GNBT) Reports IND from FDA for Phase II Combination Study Using AE37 Plus Keytruda (pembrolizumab) for Treatment of Triple Negative Breast Cancer
-
Generex Biotechnology (GNBT) to Acquire 51% Stake of Regentys Corp.
-
Generex Biotechnology (GNBT) Files IND for Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda) for Treatment of Triple-Negative Breast Cancer
-
Generex Biotech (GNBT) Unit Publishes White Paper Promoting Ii-Key in Ebola Vaccine Development
-
Generex Biotechnology (GNBT) Provides Update on Generex Oral-lyn Clinical & Regulatory Program
-
Generex (GNBT) Unit Receives U.S. Patent Notice of Allowance for AE37 Cancer Vaccine
-
Generex (GNBT) and RXi Pharma (RXII) Announce Positive RNAi Development Data
-
After-Hours Movers 10/19: WSCI, DEAR, HA, SYK, STSA, BSX, GILD Higher; GBE, FSII, CREE, MRTN, PVSW, ISRG, JNPR, YHOO Lower
-
Generex Biotechnology (GNBT) Removes From NASDAQ; Begins Trading on OTC Market
-
Generex Biotech (GNBT) to Be Delisted from Nasdaq; to Continue Production Development Initiatives
-
Morning Movers 10/11: ASTI, GYMB, INOC, GNBT, HRBN, ARTW, FTK, LDK Higher; ALXA, ARP, VQ Lower
-
Generex Biotech (GNBT) Announces a Stock Rights Offering of No Less than $25M
-
Generex Biotech (GNBT) To Acquire Majority Interest in Global Medical Direct; Board Approves Reverse Stock Split
-
Generex Biotech (GNBT) trading halted with news pending
-
Generex Biotech (GNBT) Appoints Mark Fletcher as Interim CEO, John Barratt Chairman
-
Generex Biotechnology (GNBT) Announces Approval of Adjournment Proposal Special Meeting Date
-
Generex Biotech (GNBT) Signs Mexican Distribution Agreement with Merck
-
Generex Biotech (GNBT) Announces Positive Oral-Lyn Phase III Update; Achieves 75% Per-Protocol Completers
-
Generex Biotech (GNBT) Announces Positive Nasdaq Continued Listing Determination
-
Generex Biotech's (GNBT) Glucose RapidSpray Now Available in Boots UK Stores
-
Generex Biotech (GNBT) Subsidiary Granted U.S. Patent for AE37 Immunotherapeutic Vaccine
-
Generex Biotech (GNBT) Reports Preliminary Data from Oral-Lyn Phase 3
-
Generex Biotech. (GNBT) Awarded New Patents in Japan and Ukraine
-
Generex Biotech (GNBT) Publishes AE37 Phase I Results
-
Generex Biotech (GNBT) Receives Patent Covering Insulin Administration in the Buccal Region
-
Generex Biotech (GNBT) Establishes Action Plan for Oral-Lyn Cost Reimbursement
-
Generex Biotech (GNBT) Updates on Ora-lyn Expanded Access Treatment IND Program
-
Generex Biotech (GNBT) Announces Funding Commitment from Seaside 88; Expected to Purchase Up to 49.46M Common
-
Generex Biotech (GNBT) Files $250M Suit Vs. TheStreet.com (TSCM) and Adam Feuerstein
-
Swine Flu Stocks See Interest As Hospitalizations In Georgia Rise To Highest Rate Since October
-
Generex Biotech (GNBT) Announces Generex Oral-Lyn Treatment Program Expansion
-
Generex Biotech (GNBT) Corrects Article Published on TheStreet.com (TSCM) Regarding Oral-lyn
-
Generex Biotech (GNBT) Announces Development of Key Strategic Distribution Relationships for Oral-Lyn
-
Generex Biotech (GNBT) Receives $800K in Initial Purchase Orders for Crave-NX Diet Spray
-
Generex Biotech (GNBT) Reaches Agreement to Market Crave-NX Spray Through Major Nationwide Pharmacy
-
Trading Radar for 12/23: 3com (COMS), Origin Agritech (SEED), Thestreet.com (TSCM) Report
-
Generex Biotech (GNBT) Presents Interim Phase II Immunotherapeutic Vaccine Results at SABCS
-
Generex Biotechnology (GNBT) Up After Recombinant Human Insulin Deal with Sanofi-Aventis
-
Generex (GNBT) and Sanofi (SNY) Ink Insulin Deal
-
Swine Flu Cases Decline to Lowest Level in 2+ Months
-
Morning Movers 12/03: ICOC, KTCC, FFHL, GNBT, ABK, ISR Higher; PEIX, GRH, OPXA, TRGT, ALOY Lower
-
Generex Biotech (GNBT) Announces Crave-NX Diet Spray To Be Available at 256 Duane's Locations
-
Generex (GNBT) Announces FDA Price Approval for Generex Oral-lyn in the Treatment IND Program
-
Generex Biotechnology's (GNBT) MENA Office Broadens International Reach
-
Generex (GNBT) to Raise $12,250,000 in Registered Direct Offering At $0.80 Per Share
-
Morning Movers 9/10: DVAX, DARA, GNBT, XRTX, NCS Higher; PLAB, SEH, NAV Lower
-
FDA Grants Approval for Treatment Use of Generex (GNBT) Oral-lyn(TM) Under IND Program
Back to GNBT Stock Lookup